红禾麻的研究进展
|
摘要
整理及分析苗族药(简称苗药)红禾麻的研究文献,概述其论文分布、化学成分、药理活性、质量控制、临床应用与专利获批状况,为红禾麻的后续临床应用和开发利用提供参考依据。以中国知网与Pub Med数据库作为检索平台,检索项选择关键词、全文,分别以红禾麻,红活麻,珠芽艾麻,Laportea bulbifera(Siebold&Zuccarini) Weddell.和Laportea bulbifera为检索词,检索红禾麻1989—2018年国内外的论文报道与专利获批情况。共查得论文41余篇,专利63项,论文内容以药理活性、化学成分和质量控制研究为主,专利以复方居多。目前从红禾麻中分离鉴定了73个化学成分,其中以黄酮类化合物为主。质量控制指标多选择黄酮类、儿茶素类以及香豆素类成分,药理活性以抗炎镇痛、抗风湿研究居多。红禾麻消炎镇痛、抗风湿作用显著,极具市场竞争力,但地方标准质量控制水平较低、检测项目不全。文献报道的含量测定方法缺乏专属性指标来评价红禾麻药材质量优劣,同时,还需深入研究其抗炎作用机制,发掘其质量标志物并建立谱效关系,从而有效控制红禾麻药材质量,为该药材的综合利用和资源开发提供文献资料。
The research literature of Laportea bulbifera was summarized and analyzed,and its distribution of literature,chemical composition,pharmacological activity,quality control,clinical application and patent approval were summarized,this study can provide reference for the follow-up clinical application and development and utilization of the herb. Taking CNKI and PubMed database as the retrieval platform,keywords and full text as the search items,the Honghema,Honghuoma,Zhuya Aima,Laportea bulbifera( Siebold & Zuccarini) Weddell.and Laportea bulbifera as the search terms,the domestic and foreign paper reports and patent approvals of L.bulbifera from 1989 to 2018 were retrieved. A total of 41 papers and 63 patents were reviewed,the contents of these papers were pharmacological activity,chemical composition and quality control research,the majority of patents were compound. At present,73 chemical constituents have been isolated and identified from L. bulbifera,and most of them were flavonoids. Flavonoids,catechins and coumarins were selected as the quality control indexes,and most of the pharmacological activities were anti-inflammatory,analgesic and anti-rheumatism. L. bulbifera is highly competitive in the market because of its remarkable pharmacological activities,however,its quality control level in local standard is low and testing items are incomplete. The determination reported in the literature lacks specific indexes to evaluate the quality of L. bulbifera,at the same time,it is necessary to further study its antiinflammatory mechanism,explore its quality markers and establish the spectrum-effect relationship,so as to effectively control the quality of L. bulbifera and provide documentation for its comprehensive utilization and resource development.
The research literature of Laportea bulbifera was summarized and analyzed,and its distribution of literature,chemical composition,pharmacological activity,quality control,clinical application and patent approval were summarized,this study can provide reference for the follow-up clinical application and development and utilization of the herb. Taking CNKI and PubMed database as the retrieval platform,keywords and full text as the search items,the Honghema,Honghuoma,Zhuya Aima,Laportea bulbifera( Siebold & Zuccarini) Weddell.and Laportea bulbifera as the search terms,the domestic and foreign paper reports and patent approvals of L.bulbifera from 1989 to 2018 were retrieved. A total of 41 papers and 63 patents were reviewed,the contents of these papers were pharmacological activity,chemical composition and quality control research,the majority of patents were compound. At present,73 chemical constituents have been isolated and identified from L. bulbifera,and most of them were flavonoids. Flavonoids,catechins and coumarins were selected as the quality control indexes,and most of the pharmacological activities were anti-inflammatory,analgesic and anti-rheumatism. L. bulbifera is highly competitive in the market because of its remarkable pharmacological activities,however,its quality control level in local standard is low and testing items are incomplete. The determination reported in the literature lacks specific indexes to evaluate the quality of L. bulbifera,at the same time,it is necessary to further study its antiinflammatory mechanism,explore its quality markers and establish the spectrum-effect relationship,so as to effectively control the quality of L. bulbifera and provide documentation for its comprehensive utilization and resource development.
引文
[1]中国科学院西北植物研究所.秦岭植物志.第1卷.第2册[M].北京:科学出版社,1974:104.
[2]万定荣,陈家春,余汉华.湖北药材志[M].武汉:湖北科学技术出版社,2002:24-28.
[3]贵州省药品监督管理局.贵州省中药材、民族药材质量标准[M].贵阳:贵州科技出版,2003:187.
[4]国家中医药管理局《中华本草》编委会.中华本草.苗药卷[M].贵阳:贵州科技出版社,2005:283-284.
[5] YANG M C,Choi S Z,Lee S O,et al. Flavonoid constituents and their antioxidant activity of Laportea bulbifera Weddell[J]. Korean J Pharmacogn,2003,34(1):18-24.
[6]唐娟,吴耽,陈思颖,等.基于UPLC-ESI-Q-TOF-MS的红禾麻提取物化学成分分析[J].中国实验方剂学杂志,2018,24(24):67-72.
[7]李博,卢轩,冯宝民,等.珠芽艾麻中的黄酮类成分[C]//中国化学会.中国化学会第十一届全国天然有机化学学术会议论文集(第三册):2016年卷.北京:中国学术期刊(光盘版)电子杂志社,2016:38.
[8]韩红园.民族药红活麻抗炎物质基础及体内代谢初步研究[D].北京:北京中医药大学,2018.
[9]时庆欣.红禾麻降血脂作用机理及其药效物质基础研究[D].武汉:湖北中医药大学,2018.
[10] HOU W R,SU Z Q,PI H F,et al. Immunosuppressive constituents from Urtica dentata Hand.[J]. J Asian Nat Prod Res,2010,12(8):707-713.
[11]汪石丽.红禾麻抗炎镇痛物质基础及质量控制研究[D].贵阳:贵阳医学院,2015.
[12]卢轩,张杨,冯宝民,等.珠芽艾麻化学成分研究[C]//中国化学会.中国化学会第30届学术年会摘要集:2016年卷.北京:中国学术期刊(光盘版)电子杂志社,2016:304.
[13]朱珠,马琳,朱海燕,等.民族药珠芽艾麻化学成分研究[J].中药材,2011,34(2):223-225.
[14]苏有瑞,嵇莹莹,龚国清.治疗类风湿关节炎的新靶点研究进展[J].中国新药杂志,2017,26(17):2019-2025.
[15]马琳,梁冰,朱珠,等.民族药珠芽艾麻醇提物镇痛药理作用的研究[J].贵阳中医学院学报,2012,34(1):24-26.
[16]苏志强,赵增宇,谢胜男,等.红活麻提取物镇痛抗炎和免疫抑制活性研究[J].中国药理学通报,2009,25(4):559-560.
[17]王欣,邹晓蕾,苏志强,等.红活麻乙酸乙酯有效部位对小鼠骨髓来源树突状细胞的影响[J].中华实验外科杂志,2007,24(11):1414-1416.
[18]向明,陶恩,储潼,等.红活麻有效部位干预Ⅱ型胶原所致关节炎的作用[J].中国医院药学杂志,2006,26(10):1201-1205.
[19]姚瑶.红活麻有效部位对类风湿关节炎的治疗作用和机制研究[D].武汉:华中科技大学,2008.
[20] LUO X,LI L L,ZHANG S S,et al. Therapeutic effects of total coumarins from Urtica dentata Hand on collageninduced arthritis in Balb/c mice[J]. J Ethnopharmacol,2011,138(2):523-529.
[21]骆翔.红麻素抗类风湿性关节炎作用及诱导免疫耐受机制研究[D].武汉:华中科技大学,2010.
[22]邹淑涵.苗药红禾麻质量控制及抗氧化、抗炎活性谱效关系初步研究[D].贵阳:贵阳中医学院,2017.
[23] WANG J,LU J L,LAN Y,et al. Total coumarins from Urtica dentata Hand prevent murine autoimmune diabetes via suppression of the TLR4-signaling pathways[J]. J Ethnopharmacol,2013,146(1):379-392.
[24] XIANG M, HOU W R, XIE S N, et al.Immunosuppressive effects of an ethyl acetate extract from Urtica dentata Hand on skin allograft rejection[J].J Ethnopharmacol,2009,126(1):57-63.
[25]鲁憬莉,李伟杰,侯文睿,等.红活麻总香豆素对葡聚糖硫酸钠所致小鼠结肠炎的作用研究[J].中国中药杂志,2012,37(21):3316-3320.
[26]赵增宇.红活麻总黄酮的制备及防治T2DM-IR作用研究[D].武汉:华中科技大学,2009.
[27]万定荣,冯颂桥,李安娟.民族药红活麻与活麻的生药鉴定[J].中草药,1989,20(1):34-36.
[28]孙庆文,徐文芬,齐维娜,等.苗药红禾麻与易混品艾麻的生药鉴别研究[J].中药材,2015,38(9):1862-1867.
[29]孙庆文,徐文芬,齐维娜,等.苗药红禾麻种质资源的形态变异研究[J].种子,2015,34(4):59-63.
[30]齐维娜,徐文芬,孙庆文,等.苗药红禾麻种质资源遗传多样性的ISSR分析[J].贵州科学,2017,35(1):13-18.
[31]邹淑涵,陈胤睿,徐文芬,等.苗族药红禾麻黄酮类成分与环境因子的灰色关联度分析[J].中国实验方剂学杂志,2016,22(16):30-35.
[32]邹淑涵,杨勇,温迪,等.苗药红禾麻种质资源药材中多糖含量及与环境因子的相关性分析[J].种子,2016,35(8):60-64.
[33]汪石丽,李勇军,廖尚高,等. HPLC同时测定黔产红禾麻中4种儿茶素类成分含量[J].中国实验方剂学杂志,2014,20(21):91-94.
[34] XIANG M,LU J L,ZHANG C,et al. Identification and quantification of total coumarins from Urtica dentata Hand and its roles in promoting immune tolerance via TLR4-mediated dendritic cell immaturation[J]. Biosci Biotechnol Biochem,2013,77(6):1200-1206.
[35]刘利平,成小璐,严福林,等.不同加工方法对红禾麻药材质量的影响[J].贵州科学,2017,35(5):8-12.
[36]刘栋梁,林开中.苗族与布依族的骨伤民间疗法[J].中国民族医药杂志,1998,4(4):32.
[37]文明昌,文江波,蒙景慧,等.苗药卒中康复方治疗缺血性中风临床体会[J].中国民族医药杂志,2009,15(7):28-29,40.
[38]杨必金.红活麻风湿酒治疗风湿病[C]//中国民族医药学会.全国土家族苗族医药学术会议论文专辑:2002年卷.北京:中国学术期刊(光盘版)电子杂志社,2002:73-74.
[39]刘钟,李东升.润燥止痒胶囊治疗几种常见皮肤疾病的现状[J].中国医学文摘(皮肤科学),2015,32(6):690-694.
[40]杨相波,田蓓,王新村,等.贵州苗药红禾麻的主要病虫害种类调查及防治[J].贵州农业科学,2016,44(9):78-79.
[41]杜富强,黄明喆,魏怡冰,等.苗药红禾麻(Laportea bulbifera)扦插繁殖试验[J].北方园艺,2018(18):126-131.
[2]万定荣,陈家春,余汉华.湖北药材志[M].武汉:湖北科学技术出版社,2002:24-28.
[3]贵州省药品监督管理局.贵州省中药材、民族药材质量标准[M].贵阳:贵州科技出版,2003:187.
[4]国家中医药管理局《中华本草》编委会.中华本草.苗药卷[M].贵阳:贵州科技出版社,2005:283-284.
[5] YANG M C,Choi S Z,Lee S O,et al. Flavonoid constituents and their antioxidant activity of Laportea bulbifera Weddell[J]. Korean J Pharmacogn,2003,34(1):18-24.
[6]唐娟,吴耽,陈思颖,等.基于UPLC-ESI-Q-TOF-MS的红禾麻提取物化学成分分析[J].中国实验方剂学杂志,2018,24(24):67-72.
[7]李博,卢轩,冯宝民,等.珠芽艾麻中的黄酮类成分[C]//中国化学会.中国化学会第十一届全国天然有机化学学术会议论文集(第三册):2016年卷.北京:中国学术期刊(光盘版)电子杂志社,2016:38.
[8]韩红园.民族药红活麻抗炎物质基础及体内代谢初步研究[D].北京:北京中医药大学,2018.
[9]时庆欣.红禾麻降血脂作用机理及其药效物质基础研究[D].武汉:湖北中医药大学,2018.
[10] HOU W R,SU Z Q,PI H F,et al. Immunosuppressive constituents from Urtica dentata Hand.[J]. J Asian Nat Prod Res,2010,12(8):707-713.
[11]汪石丽.红禾麻抗炎镇痛物质基础及质量控制研究[D].贵阳:贵阳医学院,2015.
[12]卢轩,张杨,冯宝民,等.珠芽艾麻化学成分研究[C]//中国化学会.中国化学会第30届学术年会摘要集:2016年卷.北京:中国学术期刊(光盘版)电子杂志社,2016:304.
[13]朱珠,马琳,朱海燕,等.民族药珠芽艾麻化学成分研究[J].中药材,2011,34(2):223-225.
[14]苏有瑞,嵇莹莹,龚国清.治疗类风湿关节炎的新靶点研究进展[J].中国新药杂志,2017,26(17):2019-2025.
[15]马琳,梁冰,朱珠,等.民族药珠芽艾麻醇提物镇痛药理作用的研究[J].贵阳中医学院学报,2012,34(1):24-26.
[16]苏志强,赵增宇,谢胜男,等.红活麻提取物镇痛抗炎和免疫抑制活性研究[J].中国药理学通报,2009,25(4):559-560.
[17]王欣,邹晓蕾,苏志强,等.红活麻乙酸乙酯有效部位对小鼠骨髓来源树突状细胞的影响[J].中华实验外科杂志,2007,24(11):1414-1416.
[18]向明,陶恩,储潼,等.红活麻有效部位干预Ⅱ型胶原所致关节炎的作用[J].中国医院药学杂志,2006,26(10):1201-1205.
[19]姚瑶.红活麻有效部位对类风湿关节炎的治疗作用和机制研究[D].武汉:华中科技大学,2008.
[20] LUO X,LI L L,ZHANG S S,et al. Therapeutic effects of total coumarins from Urtica dentata Hand on collageninduced arthritis in Balb/c mice[J]. J Ethnopharmacol,2011,138(2):523-529.
[21]骆翔.红麻素抗类风湿性关节炎作用及诱导免疫耐受机制研究[D].武汉:华中科技大学,2010.
[22]邹淑涵.苗药红禾麻质量控制及抗氧化、抗炎活性谱效关系初步研究[D].贵阳:贵阳中医学院,2017.
[23] WANG J,LU J L,LAN Y,et al. Total coumarins from Urtica dentata Hand prevent murine autoimmune diabetes via suppression of the TLR4-signaling pathways[J]. J Ethnopharmacol,2013,146(1):379-392.
[24] XIANG M, HOU W R, XIE S N, et al.Immunosuppressive effects of an ethyl acetate extract from Urtica dentata Hand on skin allograft rejection[J].J Ethnopharmacol,2009,126(1):57-63.
[25]鲁憬莉,李伟杰,侯文睿,等.红活麻总香豆素对葡聚糖硫酸钠所致小鼠结肠炎的作用研究[J].中国中药杂志,2012,37(21):3316-3320.
[26]赵增宇.红活麻总黄酮的制备及防治T2DM-IR作用研究[D].武汉:华中科技大学,2009.
[27]万定荣,冯颂桥,李安娟.民族药红活麻与活麻的生药鉴定[J].中草药,1989,20(1):34-36.
[28]孙庆文,徐文芬,齐维娜,等.苗药红禾麻与易混品艾麻的生药鉴别研究[J].中药材,2015,38(9):1862-1867.
[29]孙庆文,徐文芬,齐维娜,等.苗药红禾麻种质资源的形态变异研究[J].种子,2015,34(4):59-63.
[30]齐维娜,徐文芬,孙庆文,等.苗药红禾麻种质资源遗传多样性的ISSR分析[J].贵州科学,2017,35(1):13-18.
[31]邹淑涵,陈胤睿,徐文芬,等.苗族药红禾麻黄酮类成分与环境因子的灰色关联度分析[J].中国实验方剂学杂志,2016,22(16):30-35.
[32]邹淑涵,杨勇,温迪,等.苗药红禾麻种质资源药材中多糖含量及与环境因子的相关性分析[J].种子,2016,35(8):60-64.
[33]汪石丽,李勇军,廖尚高,等. HPLC同时测定黔产红禾麻中4种儿茶素类成分含量[J].中国实验方剂学杂志,2014,20(21):91-94.
[34] XIANG M,LU J L,ZHANG C,et al. Identification and quantification of total coumarins from Urtica dentata Hand and its roles in promoting immune tolerance via TLR4-mediated dendritic cell immaturation[J]. Biosci Biotechnol Biochem,2013,77(6):1200-1206.
[35]刘利平,成小璐,严福林,等.不同加工方法对红禾麻药材质量的影响[J].贵州科学,2017,35(5):8-12.
[36]刘栋梁,林开中.苗族与布依族的骨伤民间疗法[J].中国民族医药杂志,1998,4(4):32.
[37]文明昌,文江波,蒙景慧,等.苗药卒中康复方治疗缺血性中风临床体会[J].中国民族医药杂志,2009,15(7):28-29,40.
[38]杨必金.红活麻风湿酒治疗风湿病[C]//中国民族医药学会.全国土家族苗族医药学术会议论文专辑:2002年卷.北京:中国学术期刊(光盘版)电子杂志社,2002:73-74.
[39]刘钟,李东升.润燥止痒胶囊治疗几种常见皮肤疾病的现状[J].中国医学文摘(皮肤科学),2015,32(6):690-694.
[40]杨相波,田蓓,王新村,等.贵州苗药红禾麻的主要病虫害种类调查及防治[J].贵州农业科学,2016,44(9):78-79.
[41]杜富强,黄明喆,魏怡冰,等.苗药红禾麻(Laportea bulbifera)扦插繁殖试验[J].北方园艺,2018(18):126-131.